



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Clinafloxacin (Standard)

Cat. No.:	HY-B0536R
CAS No.:	105956-97-6
Molecular Formula:	C ₁₇ H ₁₇ ClFN ₃ O ₃
Molecular Weight:	365.79
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Clinafloxacin (Standard) is the analytical standard of Clinafloxacin. This product is intended for research and analytical applications. Clinafloxacin (AM 1091) is a potent and broad-spectrum fluoroquinolone antibiotic, has inhibitory activity against gram-positive, gram-negative bacteria, and anaerobic pathogens in vitro ^[1] . Clinafloxacin is against DNA gyrase and topoisomerase IV of <i>S. aureus</i> with IC ₅₀ values of 0.92 µg/ml and 1.62 µg/ml, respectively ^[2] .
IC ₅₀ & Target	MIC: 1 µg/ml (parC-gyrA mutants, <i>S. pneumoniae</i>) ^[1]

REFERENCES

- [1]. M Takei, et al. Target preference of 15 quinolones against *Staphylococcus aureus*, based on antibacterial activities and target inhibition. *Antimicrob Agents Chemother.* 2001 Dec;45(12):3544-7.
- [2]. Randa H Abdelkreem, et al. DNA Gyrase and Topoisomerase IV Mutations and their effect on Quinolones Resistant *Proteus mirabilis* among UTIs Patients. *Pak J Med Sci.* Sep-Oct 2020;36(6):1234-1240.
- [3]. A Domenech, et al. Experimental study of clinafloxacin alone and in combination in the treatment of ciprofloxacin-susceptible and -resistant pneumococcal meningitis. *Microb Drug Resist.* 2003;9 Suppl 1:S53-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA